Unique ID issued by UMIN | UMIN000001537 |
---|---|
Receipt number | R000001844 |
Scientific Title | Phase III randomized trial of combined androgen deprivation with high dose rate brachytherapy in locally advanced prostate cancer |
Date of disclosure of the study information | 2008/12/01 |
Last modified on | 2016/04/27 13:55:33 |
Phase III randomized trial of combined androgen deprivation with high dose rate brachytherapy in locally advanced prostate cancer
Phase III randomized trial of combined androgen deprivation with high dose rate brachytherapy in locally advanced prostate cancer
Phase III randomized trial of combined androgen deprivation with high dose rate brachytherapy in locally advanced prostate cancer
Phase III randomized trial of combined androgen deprivation with high dose rate brachytherapy in locally advanced prostate cancer
Japan |
Prostate cancer
Urology |
Malignancy
NO
1. To evaluate the biochemical progression-free survival of patients with locally advanced prostate cancer treated by high dose rate brachytherapy and external beam radiotherapy combined with long-term (40 months) hormonal therapy in comparison with short-term (4 months) hormonal therapy.
2. Surrogate end points of this clinical trial are overall survival, cause specific survival and clinical progression-free survival, QOL and safety.
Safety,Efficacy
Confirmatory
Pragmatic
Phase III
Biochemical progression-free survival (PFS)
Overall survival
Cause- specific survival
Clinical progression-free survival
QOL
Safety
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
No treatment
NO
YES
NO
Central registration
2
Treatment
Medicine | Maneuver |
Patients receive neoadjuvant hormonal therapy for three months and undergo high dose rate brachytherapy and external radiation therapy with concurrent hormonal therapy. Patients then receive adjuvant hormonal therapy for up to 36 months.
Patients receive neoadjuvant hormonal therapy for three months and undergo high dose rate brachytherapy and external radiation therapy with concurrent hormonal therapy. Patients are followed up without adjuvant hormonal therapy.
20 | years-old | <= |
80 | years-old | >= |
Male
1. Histologically confirmed adenocarcinoma of the prostate
2. Previously untreated disease
3. Prostate-Specific Antigen (PSA) 20.1-100 ng/mL
4. T2N0M0(Gleason score >or= 8) or T3N0M0(Any Gleason score)
5. Rate of positive core of prostate biopsy >or= 50%
6. ECOG performance status 0-1
7. Age <or= 80
1. Patients with other cancer requiring treatment
2. Patients with serious complications
3. Patients who fall under the following(Leukocyte count < 3,000/uL, Hemoglobin < 10.0g/dL, Platelet count < 75,000/uL, AST, ALT and ALP > 2.5 times upper limit of normal (ULN), Serum Creatinine > 1.5 times ULN)
120
1st name | |
Middle name | |
Last name | Isao Hara |
Wakayama Medical University
Department of Urology
811-1, Kimiidera, Wakayama City, Wakayama, 641-8590, Japan
073-441-0637
hara@wakayama-med.ac.jp
1st name | |
Middle name | |
Last name | Isco Hara, M.D. |
Wakayama Medical University
Department of Urology
811-1, Kimiidera, Wakayama City, Wakayama, 641-8590, Japan
073-441-0637
hara@wakayama-med.ac.jp
Wakayama Medical University, Department of Urology
Department of Urology
Wakayama Medical University
Local Government
None
None
NO
2008 | Year | 12 | Month | 01 | Day |
Unpublished
Open public recruiting
2008 | Year | 09 | Month | 16 | Day |
2008 | Year | 11 | Month | 01 | Day |
2020 | Year | 09 | Month | 01 | Day |
2008 | Year | 12 | Month | 01 | Day |
2016 | Year | 04 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001844
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |